OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs

Background: Pharmacological targeting aberrant activation of epidermal growth factor receptor tyrosine kinase signaling is an established approach to treating lung adenocarcinoma. Osimertinib is a tyrosine kinase approved and effective in treating lung adenocarcinomas that have one of several common...

Full description

Bibliographic Details

Published in:	Cells
Main Authors:	Richard E. Kast, Marc-Eric Halatsch, Rafael Rosell
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Subjects:	EGFR NSCLC osimertinib repurposing cancer stem cells
Online Access:	https://www.mdpi.com/2073-4409/10/5/1148